Literature DB >> 25934441

A Murine Model of K-RAS and β-Catenin Induced Renal Tumors Expresses High Levels of E2F1 and Resembles Human Wilms Tumor.

Yajun Yi1, Dina Polosukhina1, Harold D Love1, Austin Hembd1, Michael Pickup1, Harold L Moses1, Harold N Lovvorn1, Roy Zent1, Peter E Clark2.   

Abstract

PURPOSE: Wilms tumor is the most common renal neoplasm of childhood. We previously found that restricted activation of the WNT/β-catenin pathway in renal epithelium late in kidney development is sufficient to induce small primitive neoplasms with features of epithelial Wilms tumor. Metastatic disease progression required simultaneous addition of an activating mutation of the oncogene K-RAS. We sought to define the molecular pathways activated in this process and their relationship to human renal malignancies.
MATERIALS AND METHODS: Affymetrix® expression microarray data from murine kidneys with activation of K-ras and/or Ctnnb1 (β-catenin) restricted to renal epithelium were analyzed and compared to publicly available expression data on normal and neoplastic human renal tissue. Target genes were verified by immunoblot and immunohistochemistry.
RESULTS: Mouse kidney tumors with activation of K-ras and Ctnnb1, and human renal malignancies had similar mRNA expression signatures and were associated with activation of networks centered on β-catenin and TP53. Up-regulation of WNT/β-catenin targets (MYC, Survivin, FOXA2, Axin2 and Cyclin D1) was confirmed by immunoblot. K-RAS/β-catenin murine kidney tumors were more similar to human Wilms tumor than to other renal malignancies and demonstrated activation of a TP53 dependent network of genes, including the transcription factor E2F1. Up-regulation of E2F1 was confirmed in murine and human Wilms tumor samples.
CONCLUSIONS: Simultaneous activation of K-RAS and β-catenin in embryonic renal epithelium leads to neoplasms similar to human Wilms tumor and associated with activation of TP53 and up-regulation of E2F1. Further studies are warranted to evaluate the role of TP53 and E2F1 in human Wilms tumor.
Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Wilms tumor; animal; beta catenin; kidney; models; oncogenes

Mesh:

Substances:

Year:  2015        PMID: 25934441      PMCID: PMC4782590          DOI: 10.1016/j.juro.2015.04.090

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  30 in total

1.  A role for Myc in facilitating transcription activation by E2F1.

Authors:  J Y Leung; G L Ehmann; P H Giangrande; J R Nevins
Journal:  Oncogene       Date:  2008-03-17       Impact factor: 9.867

2.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

3.  The National Cancer Data Base report on patterns of childhood cancers in the United States.

Authors:  A Grovas; A Fremgen; A Rauck; F B Ruymann; C L Hutchinson; D P Winchester; H R Menck
Journal:  Cancer       Date:  1997-12-15       Impact factor: 6.860

4.  Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.

Authors:  Jeffrey S Dome; Cecilia A Cotton; Elizabeth J Perlman; Norman E Breslow; John A Kalapurakal; Michael L Ritchey; Paul E Grundy; Marcio Malogolowkin; J Bruce Beckwith; Robert C Shamberger; Gerald M Haase; Max J Coppes; Peter Coccia; Morris Kletzel; Robert M Weetman; Milton Donaldson; Roger M Macklis; Daniel M Green
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

Review 5.  Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene.

Authors:  Vicki Huff
Journal:  Nat Rev Cancer       Date:  2011-01-20       Impact factor: 60.716

6.  Association of E2F3 expression with clinicopathological features of Wilms' tumors.

Authors:  Qun An; Yan Wang; Ruihua An; Yan Li; Ting Yao; Bo Zhai; Xueying Sun
Journal:  J Pediatr Surg       Date:  2013-11       Impact factor: 2.545

7.  e2f1 Gene is a new member of Wnt/beta-catenin/Tcf-regulated genes.

Authors:  Maria V Abramova; Evgeny A Zatulovskiy; Svetlana B Svetlikova; Alexander N Kukushkin; Valery A Pospelov
Journal:  Biochem Biophys Res Commun       Date:  2009-11-11       Impact factor: 3.575

8.  Dysregulation of β-catenin is an independent predictor of oncologic outcomes in patients with clear cell renal cell carcinoma.

Authors:  Laura-Maria Krabbe; Mary E Westerman; Aditya Bagrodia; Bishoy A Gayed; Oussama M Darwish; Ahmed Q Haddad; Dina Khalil; Payal Kapur; Arthur I Sagalowsky; Yair Lotan; Vitaly Margulis
Journal:  J Urol       Date:  2013-11-26       Impact factor: 7.450

Review 9.  E2F1 apoptosis counterattacked: evil strikes back.

Authors:  Brigitte M Pützer; David Engelmann
Journal:  Trends Mol Med       Date:  2012-12-05       Impact factor: 11.951

10.  Beta-catenin expression and mutation in adult and pediatric Wilms' tumors.

Authors:  Min-Cheng Su; Wan-Chen Huang; Huang-Chun Lien
Journal:  APMIS       Date:  2008-09       Impact factor: 3.205

View more
  9 in total

1.  FXR1 expression domain in Wilms tumor.

Authors:  Hannah M Phelps; Janene M Pierce; Andrew J Murphy; Hernan Correa; Jun Qian; Pierre P Massion; Harold N Lovvorn
Journal:  J Pediatr Surg       Date:  2019-02-28       Impact factor: 2.545

2.  Investigating the dysfunctional pathogenesis of Wilms' tumor through a multidimensional integration strategy.

Authors:  Wenbiao Chen; Jia Zhuang; Lan Gong; Yong Dai; Hongyan Diao
Journal:  Ann Transl Med       Date:  2019-04

Review 3.  The Vanderbilt O'Brien Kidney Center.

Authors:  Ambra Pozzi; Raymond C Harris
Journal:  Am J Physiol Renal Physiol       Date:  2020-12-28

4.  Genetic and chromosomal alterations in Kenyan Wilms Tumor.

Authors:  Harold N Lovvorn; Janene Pierce; Jaime Libes; Bingshan Li; Qiang Wei; Hernan Correa; Julia Gouffon; Peter E Clark; Jason R Axt; Erik Hansen; Mark Newton; James A O'Neill
Journal:  Genes Chromosomes Cancer       Date:  2015-08-14       Impact factor: 5.006

5.  Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors.

Authors:  Dina Polosukhina; Harold D Love; Hernan Correa; Zengliu Su; Kimberly B Dahlman; William Pao; Harold L Moses; Carlos L Arteaga; Harold N Lovvorn; Roy Zent; Peter E Clark
Journal:  Mol Oncol       Date:  2017-03-15       Impact factor: 6.603

6.  Pharmacologic Inhibition of β-Catenin With Pyrvinium Inhibits Murine and Human Models of Wilms Tumor.

Authors:  Dina Polosukhina; Harold D Love; Harold L Moses; Ethan Lee; Roy Zent; Peter E Clark
Journal:  Oncol Res       Date:  2017-07-10       Impact factor: 5.574

7.  Identification of a gene-expression predictor for diagnosis and personalized stratification of lupus patients.

Authors:  Yan Ding; Hongai Li; Xiaojie He; Wang Liao; Zhuwen Yi; Jia Yi; Zhibin Chen; Daniel J Moore; Yajun Yi; Wei Xiang
Journal:  PLoS One       Date:  2018-07-05       Impact factor: 3.240

8.  Claudin-2 inhibits renal clear cell carcinoma progression by inhibiting YAP-activation.

Authors:  Balawant Kumar; Rizwan Ahmad; Giovanna A Giannico; Roy Zent; Geoffrey A Talmon; Raymond C Harris; Peter E Clark; Vinata Lokeshwar; Punita Dhawan; Amar B Singh
Journal:  J Exp Clin Cancer Res       Date:  2021-02-23

9.  Senescence Process in Primary Wilms' Tumor Cell Culture Induced by p53 Independent p21 Expression.

Authors:  Korkiat Theerakitthanakul; Jeerasak Khrueathong; Jirasak Kruatong; Potchanapond Graidist; Pritsana Raungrut; Kanita Kayasut; Surasak Sangkhathat
Journal:  J Cancer       Date:  2016-09-02       Impact factor: 4.207

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.